Published 2 days ago • loading... • Updated 2 days ago

Study suggests new molecular strategy for treating fragile X syndrome

Summary by Medical Xpress

Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and Memory reports a new way to treat pathology and symptoms of fragile X syndrome, the most common genetically-caused autism spectrum disorder. The team showed that augmenting a novel type of neurotransmitter signaling reduced hallmarks of fragile X in mouse models of the disorder.

2 Articles

All

Left

Center

Right

GEN - Genetic Engineering and Biotechnology News…

Fragile X Phenotypes Reversed in Mice by Targeting NMDA Receptors

A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This work shows that enhancing the function of the GluN2b subunit of the N-methyl-D-aspartate (NMDA) receptor signaling pathway can correct key neural dysfunctions in a mouse model of fragile X syndrome. The research, titled “Non-ionotropic signaling throug…

2 days ago

Read Full Article